AuthorsO'Connor, James P B
AffiliationInstitute of Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractThere is interest in identifying and quantifying tumor heterogeneity at the genomic, tissue pathology and clinical imaging scales, as this may help better understand tumor biology and may yield useful biomarkers for guiding therapy-based decision making. This review focuses on the role and value of using x-ray, CT, MRI and PET based imaging methods that identify, measure and map tumor heterogeneity. In particular we highlight the potential value of these techniques and the key challenges required to validate and qualify these biomarkers for clinical use.
CitationCancer heterogeneity and imaging. 2016 Semin Cell Dev Biol
JournalSeminars in Cell & Developmental Biology
- How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
- Authors: Farwell MD, Clark AS, Mankoff DA
- Issue date: 2015 Jul
- Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.
- Authors: O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A
- Issue date: 2015 Jan 15
- Quantifying heterogeneity in human tumours using MRI and PET.
- Authors: Asselin MC, O'Connor JP, Boellaard R, Thacker NA, Jackson A
- Issue date: 2012 Mar
- Clinical applications of spectral molecular imaging: potential and challenges.
- Authors: Anderson NG, Butler AP
- Issue date: 2014 Jan-Feb
- Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making.
- Authors: Prescott JW
- Issue date: 2013 Feb